AB0057 Increased IL-35 Serum Levels in Systemic Sclerosis Indicates Association with Pulmonary Fibrosis. (9th June 2015)

• Record Type: Journal Article
• Authors: Dantas, A.T.; Gonçalves, S.M.C.; Pereira, M.C.; Gonçalves, R.S.G.; Marques, C.D.L.; Rego, M.J.B.D.M.; Pitta, I.D.R.; Duarte, A.L.B.P.; Pitta, M.G.D.R.
• Is Part Of: Annals of the rheumatic diseases. Volume 74(2015)Supplement 2
• Page Start: 909
• Page End: 909
• Publication Date: 2015-06-09
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2015-eular.3632
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Experimental studies indicate that interleukin-35 (IL-35) is an important anti-inflammatory cytokine and can efficiently suppress T effector cell activity and reduce the progression of inflammatory and autoimmune diseases. However, its real role in the pathophysiology of human diseases is still unclear. Objectives: To assess the serum IL-35 level and its association with clinical manifestations in patients with Systemic Sclerosis (SSc). Methods: IL-35 serum levels were measured by ELISA from 56 patients with SSc and 53 healthy controls. Association of IL-35 serum levels with clinical parameters were sought. Results: Serum IL-35 levels were significantly higher in SSc patients (5.08±0.76pg/ml) than in healthy individuals (1.89±0.69 pg/ml; P<0.0001). There were no differences in serum IL-35 levels between those with limited cutaneous SSc and those with diffuse cutaneous SSc (4.87±1.07 and 5.32±1.11 pg/ml, p=0.776), but both levels were higher than control group (p<0.0001). Patients with lung fibrosis had higher IL-35 levels than those without fibrosis (7.75±1.36 and 3.08±0.70 pg/ml, respectively, p=0.0022). Regarding treatment, patients taking azathioprine had increased IL-35 levels (8.81±1.81 pg/ml) compared to those not taking (4.35±0.82 pg/ml, p=0.0220). Conclusions: IL-35 is elevated in the serum of patients with SSc and is associated with lung fibrosis. Our findings suggest that this cytokine can have a role in fibrotic diseases but further studies are needed to address the role of IL-35 in the pathogenesis of SSc. References: Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol;37:3021-9. Ouyang H, Shi YB, Liu ZC, Wang Z, Feng S, Kong SM, et al. Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci 2014;348:156-61. Disclosure of Interest: None declared